We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Novel Stent Closes Patent Foramen Ovale From Within

By HospiMedica International staff writers
Posted on 28 May 2009
An innovative Patent Foramen Ovale (PFO) closure system redefines the concept of a stent, using outward-directed force to close a structure, instead of outward expansion forces to open it. More...


The FlatStent EF is designed to combine the familiarity and ease-of-use of a self-expanding vascular stent with a unique fusion of PFO closure technologies. Rapid-exchange functionality simplifies device delivery and maintains wire access throughout the procedure. The Flatstent is designed to provide three distinct closure mechanisms; a lateral force exerted by the deployed stent to close the tunnel from within; a foreign body response to the implant to stimulate endothelial formation; and a polymer substrate to promote cellular integration within the tunnel. The mechanism of action of the FlatStent EF is also intended to limit the incidence of other major complications associated with septal patching devices currently in use, such as erosion, persistent arrhythmia, and valve apparatus distortion. Additionally, the implanted stent leaves a minimal amount of material exposed in the left atrium to reduce the risk of thromboembolism. The FlatStent EF is under development by Coherex Medical (Salt lake City, UT, USA) and is currently being used exclusively for clinical investigations in Europe and Australia.

"The Coherex FlatStent marks the beginning of a new era of medical device technology and significantly raises the bar by providing a simple and safe alternative in PFO closure for physicians and their patients," said Horst Sievert, M.D., a professor of internal medicine, cardiology, and vascular medicine at the Cardiovascular Center (Frankfurt, Germany), who completed the first human cases of the FlatStent PFO Closure System.

PFO is a common condition (affecting about 25% of the population) in which a hole that connects the two upper chambers of the heart (atria) during fetal development fails to close properly after birth. The PFO functions like a flap valve, opening under increased pressure that occurs when people strain while having a bowel movement, cough, or sneeze. If the pressure is great enough, blood may travel from the right atrium to the left atrium. If there is a clot or particles in the blood traveling in the right side of the heart, it can cross the PFO, enter the left atrium, and travel out of the heart and to the brain (causing a stroke) or into a coronary artery (causing a myocardial infarction).

Related Links:
Coherex Medical
Cardiovascular Center


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Head Rest
Medifa 61114_3
Digital Color Doppler Ultrasound System
MS22Plus
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.